CIK 0000882095
- Large accelerated filer
GILEAD SCIENCES, INC.
Sign in to watch- Ticker
- GILD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943047598
- Phone
- +1 650-574-3000
- Business address
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404
- Former names
- GILEAD SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,560,956
- in 13 filings, $41.6M under 10b5-1 plans
Net −$41,560,956. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-16 | Mercier Johanna Chief Comm & Corp Aff Officer | Exercise or conversion 10b5-1 | +25,000 | $72.34 | $1.8M | 138,684 |
| 2026-11-16 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 | −13,922 | $169.97 | $2.4M | 124,762 |
| 2026-11-16 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 | −13,178 | $171.09 | $2.3M | 111,584 |
| 2026-11-16 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 | −900 | $171.69 | $155K | 110,684 |
| 2026-11-16 | Mercier Johanna Chief Comm & Corp Aff Officer | Exercise or conversion · Non-qualified Stock Option (Right to Buy) 10b5-1 | −25,000 | 44,960 | ||
| 2026-11-16 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −3,000 | $171.47 | $514K | 158,096 |
| 2026-11-12 | Kramer Kelly A. Director | Exercise or conversion 10b5-1 | +10,376 | $66.92 | $694K | 11,715 |
| 2026-11-12 | Kramer Kelly A. Director | Sale 10b5-1 | −1,676 | $168.23 | $282K | 10,039 |
| 2026-11-12 | Kramer Kelly A. Director | Sale 10b5-1 | −3,800 | $169.44 | $644K | 6,239 |
| 2026-11-12 | Kramer Kelly A. Director | Sale 10b5-1 | −4,700 | $170.49 | $801K | 1,539 |
| 2026-11-12 | Kramer Kelly A. Director | Sale 10b5-1 | −200 | $171.44 | $34K | 1,339 |
| 2026-11-12 | Kramer Kelly A. Director | Exercise or conversion · Non-qualified Stock Option (Right to Buy) 10b5-1 | −10,376 | 0 | ||
| 2026-11-06 | Cain Wettan Keeley M EVP Gen Counsel, Legal & Comp | Sale 10b5-1 | −3,399 | $164.11 | $558K | 5,360 |
| 2026-11-05 | O'Day Daniel Patrick Chairman & CEO | Exercise or conversion 10b5-1 | +9,810 | $72.34 | $710K | 561,493 |
| 2026-11-05 | O'Day Daniel Patrick Chairman & CEO | Sale 10b5-1 | −9,810 | $175.17 | $1.7M | 551,683 |
| 2026-11-05 | O'Day Daniel Patrick Chairman & CEO | Exercise or conversion · Non-qualified Stock Option (Right to Buy) 10b5-1 | −9,810 | 128,310 | ||
| 2026-11-04 | O'Day Daniel Patrick Chairman & CEO | Exercise or conversion 10b5-1 | +102,619 | $72.34 | $7.4M | 654,302 |
| 2026-11-04 | O'Day Daniel Patrick Chairman & CEO | Sale 10b5-1 | −102,619 | $175.16 | $18.0M | 551,683 |
| 2026-11-04 | O'Day Daniel Patrick Chairman & CEO | Exercise or conversion · Non-qualified Stock Option (Right to Buy) 10b5-1 | −102,619 | 138,120 | ||
| 2026-11-02 | O'Day Daniel Patrick Chairman & CEO | Sale 10b5-1 | −1,600 | $167.40 | $268K | 565,083 |
Page 1 of 44 · 870 trades